91 related articles for article (PubMed ID: 19584444)
1. Amyloid-beta42 plasma levels are elevated in amnestic mild cognitive impairment.
Cammarata S; Borghi R; Giliberto L; Pardini M; Pollero V; Novello C; Fornaro M; Vitali A; Bracco L; Caltagirone C; Bossù P; Odetti P; Tabaton M
J Alzheimers Dis; 2009; 18(2):267-71. PubMed ID: 19584444
[TBL] [Abstract][Full Text] [Related]
2. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
[TBL] [Abstract][Full Text] [Related]
3. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.
Blasko I; Jellinger K; Kemmler G; Krampla W; Jungwirth S; Wichart I; Tragl KH; Fischer P
Neurobiol Aging; 2008 Jan; 29(1):1-11. PubMed ID: 17055615
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
Hansson O; Zetterberg H; Vanmechelen E; Vanderstichele H; Andreasson U; Londos E; Wallin A; Minthon L; Blennow K
Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment.
Pesaresi M; Lovati C; Bertora P; Mailland E; Galimberti D; Scarpini E; Quadri P; Forloni G; Mariani C
Neurobiol Aging; 2006 Jun; 27(6):904-5. PubMed ID: 16638622
[TBL] [Abstract][Full Text] [Related]
7. Plasma amyloid beta42 and amyloid beta40 levels are associated with early cognitive dysfunction after cardiac surgery.
Evered LA; Silbert BS; Scott DA; Maruff P; Laughton KM; Volitakis I; Cowie T; Cherny RA; Masters CL; Li QX
Ann Thorac Surg; 2009 Nov; 88(5):1426-32. PubMed ID: 19853085
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
Kester MI; Verwey NA; van Elk EJ; Scheltens P; Blankenstein MA
Neurobiol Aging; 2010 Apr; 31(4):539-40; author reply 541. PubMed ID: 18963255
[No Abstract] [Full Text] [Related]
9. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.
Gurol ME; Irizarry MC; Smith EE; Raju S; Diaz-Arrastia R; Bottiglieri T; Rosand J; Growdon JH; Greenberg SM
Neurology; 2006 Jan; 66(1):23-9. PubMed ID: 16401840
[TBL] [Abstract][Full Text] [Related]
10. Serum amyloid beta protein in young and elderly depression: a pilot study.
Kita Y; Baba H; Maeshima H; Nakano Y; Suzuki T; Arai H
Psychogeriatrics; 2009 Dec; 9(4):180-5. PubMed ID: 20377819
[TBL] [Abstract][Full Text] [Related]
11. Elevation of {beta}-amyloid 1-42 autoantibodies in the blood of amnestic patients with mild cognitive impairment.
Storace D; Cammarata S; Borghi R; Sanguineti R; Giliberto L; Piccini A; Pollero V; Novello C; Caltagirone C; Smith MA; Bossù P; Perry G; Odetti P; Tabaton M
Arch Neurol; 2010 Jul; 67(7):867-72. PubMed ID: 20625095
[TBL] [Abstract][Full Text] [Related]
12. Effects of medications on plasma amyloid beta (Abeta) 42: longitudinal data from the VITA cohort.
Blasko I; Jungwirth S; Jellinger K; Kemmler G; Krampla W; Weissgram S; Wichart I; Tragl KH; Hinterhuber H; Fischer P
J Psychiatr Res; 2008 Sep; 42(11):946-55. PubMed ID: 18155247
[TBL] [Abstract][Full Text] [Related]
13. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls.
Xu W; Kawarabayashi T; Matsubara E; Deguchi K; Murakami T; Harigaya Y; Ikeda M; Amari M; Kuwano R; Abe K; Shoji M
Brain Res; 2008 Jul; 1219():169-79. PubMed ID: 18534566
[TBL] [Abstract][Full Text] [Related]
14. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.
Fukumoto H; Tennis M; Locascio JJ; Hyman BT; Growdon JH; Irizarry MC
Arch Neurol; 2003 Jul; 60(7):958-64. PubMed ID: 12873852
[TBL] [Abstract][Full Text] [Related]
15. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
[TBL] [Abstract][Full Text] [Related]
16. Plasma biomarkers of Alzheimer's disease.
Kawarabayashi T; Shoji M
Curr Opin Psychiatry; 2008 May; 21(3):260-7. PubMed ID: 18382225
[TBL] [Abstract][Full Text] [Related]
17. Increased amyloid beta protein levels in children and adolescents with Down syndrome.
Mehta PD; Capone G; Jewell A; Freedland RL
J Neurol Sci; 2007 Mar; 254(1-2):22-7. PubMed ID: 17275850
[TBL] [Abstract][Full Text] [Related]
18. Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study.
Albani D; Marizzoni M; Ferrari C; Fusco F; Boeri L; Raimondi I; Jovicich J; Babiloni C; Soricelli A; Lizio R; Galluzzi S; Cavaliere L; Didic M; Schönknecht P; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Bocchio L; Salvatore M; Rossini PM; Tsolaki M; Visser PJ; Richardson JC; Wiltfang J; Bordet R; Blin O; Forloni G; Frisoni GB;
J Alzheimers Dis; 2019; 69(1):37-48. PubMed ID: 30149449
[TBL] [Abstract][Full Text] [Related]
19. Abnormal functional connectivity of hippocampus during episodic memory retrieval processing network in amnestic mild cognitive impairment.
Bai F; Zhang Z; Watson DR; Yu H; Shi Y; Yuan Y; Zang Y; Zhu C; Qian Y
Biol Psychiatry; 2009 Jun; 65(11):951-8. PubMed ID: 19028382
[TBL] [Abstract][Full Text] [Related]
20. Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease.
Buchhave P; Janciauskiene S; Zetterberg H; Blennow K; Minthon L; Hansson O
Neurosci Lett; 2009 Jan; 450(1):56-9. PubMed ID: 18996438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
